Skyvira® is included in the updated list of medicines for COVID-19
The current version of the guidelines for the prevention, diagnosis and treatment of coronavirus infection, which was developed by leading Russian experts in infectious diseases, is available on the website of the Russian Ministry of Health. The list of drug products also includes a new drug Skyvira® manufactured by Promomed Group.
A drug for targeted etiotropic therapy of COVID-19, based on nirmatrelvir and ritonavir, created using a unique technology and belonging to a new generation of drugs. Skyvira® acts on completely different targets specific to the coronavirus. In other words, the drug completely blocks the process of reproduction of the virus inside the cell. Ritonavir, acting as a pharmacokinetic enhancer, helps to maintain the desired concentration of nirmatrelvir in the body for a long time and increases the effectiveness of therapy.
«In clinical trials the new drug demonstrated a significant antiviral effect in the treatment of COVID-19, reduced the risk of disease progression into more severe forms and accelerated recovery. The mechanism of action targeted at viral protease determines the success of treatment regardless of the strain of SARS-CoV-2. Today, Skyvira by Promomed can be used for outpatient treatment of mild or moderate coronavirus infection in adults,» said Vladimir Chulanov, Chief Non-Staff Specialist in Infectious Diseases of the Russian Ministry of Health, Deputy Director for Research and Innovative Development of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Russian Ministry of Health.
«Each new drug in the Promomed’s antiviral portfolio provides an opportunity for a more personalized approach to patient treatment, taking into account concomitant diseases, drug interactions, duration of symptoms, and so on, and, consequently, more effective treatment,» commented Kira Zaslavskaya, Director for New Products at Promomed Group.
For the treatment of COVID-19 in adults, the following regime is indicated: daily dose of 600 mg of nirmatrelvir + 200 mg of ritonavir (1 tablet 2 times a day) for 5 days. It is recommended to start treatment as early as possible after the diagnosis of a new coronavirus infection and/or within 5 days after the onset of the first symptoms of the disease.
